SCHEMBL6498182

SCHEMBL6498182

Cc1nc2ccc(C(=O)O)nc2n1Cc1ccc(-c2ccccc2)nc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 7/20 0.39
DYRK2 Q92630 7/20 0.39
CDK9 P50750 4/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CLK1 P49759 1/20 0.38
GLP1R P43220 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492552 0.85 KMT2A (0.38) KMT2AALDH1A1MAPTSMN1; SMN2GLP1R
SCHEMBL6305658 0.83 ALDH1A1 (0.45) KMT2AALDH1A1MAPTSMN1; SMN2HDAC3
SCHEMBL6493683 0.83 PTGS2 (0.44) KMT2AALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL6299049 0.82 FAAH (0.44) KMT2AALDH1A1MAPTSMN1; SMN2HDAC3
SCHEMBL6135663 0.81 PPARG (0.51) DYRK1ACDK9KMT2AALDH1A1MAPT
SCHEMBL6299415 0.81 ALDH1A1 (0.50) DYRK1ADYRK2CDK9KMT2AALDH1A1
SCHEMBL6305366 0.79 PIK3CB (0.41) KMT2AALDH1A1MAPTSMN1; SMN2GLP1R
SCHEMBL6299786 0.78 ALDH1A1 (0.43) KMT2AALDH1A1MAPTSMN1; SMN2HDAC3
SCHEMBL6299043 0.78 PIK3CB (0.51) KMT2AALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL6299802 0.78 SMN1; SMN2 (0.44) KMT2AALDH1A1MAPTSMN1; SMN2GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A DYRK1A 2629/4885DYRK2 2798/4885CDK9 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.